The role of PDE5 inhibitors in penile septal scar remodeling: Assessment of clinical and radiological outcomes

Journal of Sexual Medicine

Volumn 8, Issue 5, 2011, Pages 1472-1477

  Chung, Eric ^a   Deyoung, Ling ^a   Brock, Gerald B ^a  

^a Division of Urology   (Canada)

Author keywords

Penile Septal Scar Remodeling; Peyronie's Disease; Phosphodiesterase Type 5 Inhibitors

Indexed keywords

TADALAFIL;

ADULT; ARTICLE; CONTROLLED STUDY; DOPPLER FLOWMETRY; FOLLOW UP; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; ISOLATED SEPTAL SCAR; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PEYRONIE DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 79955154487     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2011.02217.x     Document Type: Article

References (22)

1. Pryor J, Akkus E, Alter G, Jordan G, Lebret T, Levine L, Mulhall J, Perovic S, Ralph D, Stackl W. Peyronie's disease. J Sex Med 2004;1:110-5.
2. Aversa A, Bruzziches R, Spera G. Diagnosing erectile dysfunction: The penile dynamic duplex ultrasound revisited. Int J Androl 2005;28:61-3.
3. Smith JF, Brant WO, Fradet V, Shindel AW, Vittingoff E, Chi T, Huang YC, Davis CB, Conti S, Lue TF. Penile sonographic and clinical characteristics in men with Peyronie's disease. J Sex Med 2009;6:2858-67.
4. Breyer BN, Shindel AW, Huang YC, Eisenberg ML, Weiss DA, Lue TF, Smith JF. Are sonographic characteristics associated with progression to surgery in men with Peyronie's disease? J Urol 2010;183:1484-8.
5. Brant WO, Bella AJ, Garcia MM, Tantiwongse K, Dean RC, Lue TF. Isolated septal fibrosis or hematoma-atypical Pyeronie's disease? J Urol 2007;177:179-82. discussion 83.
6. Szollar GP, Pranikoff K, Kremzier JE. Peyronie's disease: An unusual location. J Urol 1984;132:764-5.
7. Bella AJ, Sener A, Foell K, Brock GB. Nonpalpable scarring of the penile septum as a cause of erectile dysfunction: An atypical form of Peyronie's disease. J Sex Med 2007;4:226-30.
8. Ferrini MG, Kovanecz I, Nolazco G, Rajfer J, Gonzalez-Cadavid NF. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease. BJU Int 2006;97:625-33.
9. Kovanecz I, Rambhatla A, Ferrini MG, Verdet D, Sanchez S, Rajfer J, Gonzalez-Cadavid NF. Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection. BJU Int 2008;101:203-10.
10. Kovanecz I, Rambhatla A, Ferrini M, Verdet D, Sanchez S, Rajfer J, Gonzalez-Cadavid NF. Long-term continuous sildenafil treatment ameriolates corporal veno-occlusive dysfunction (CVOD) induced by cavernosal nerve resection in rats. Int J Impot Res 2008;20:202-12.
11. Schwartz EJ, Wong P, Graydon RJ. Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy. J Urol 2004;171:771-4.
12. Smith BH. Peyronie's disease. Am J Clin Pathol 1966;45:671-3.
13. Brock G, Hsu GL, Nune L, von Heyden B, Lue TF. The anatomy of the tunica albuginea in the normal penis and Peyronie's disease. J Urol 1997;157:276-81.
14. Gonzalez-Cadavid NF. Mechanisms of penile fibrosis. J Sex Med 2009;6:353-62.
15. Bekos A, Arvaniti M, Hatzimouratidis K, Moysidis K, Tzortzis V, Hatzichristou D. The natural history of Peyronie's disease: An ultrasonography-based study. Eur Urol 2008;53:644-50.
16. Lopez JA, Jarow JP. Duplex ultrasound findings in men with Peyronie's disease. Urol Radiol 1991;12:199-202.
17. El-Sakka AI, Hassoba HM, Chui RM, Bhatnagar RS, Dahiya R, Lue TF. An animal model of Peyronie's-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J Urol 1997;158:2284-90.
18. Valente EG, Vernet D, Ferrini MG, Qian A, Rajner J, Gonzalez-Cadavid NF. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide 2003;9:229-44.
19. Vernet D, Ferrini MG, Valente EG, Qian A, Rajner J, Gonzalez-Cadavid NF. Effect of nitric oxide on the differentiation of fibroblast into myofibroblast in the Peyronie's fibrotic plaque and in its rat model. Nitric Oxide 2002;7:262-76.
20. Tsuruda T, Costello-Boerrigter LC, Burnett JC Jr. Matrix metalloproteinases: Pathways of induction by bioactive molecules. Heart Fail Rev 2004;9:53-61.
21. Shindel AW, Lin G, Ning H, Banie L, Huang YC, Liu G, Lin CS, Lue TF. Pentoxifylline attenuates transforming growth factor-β1-stimulated collagen deposition and elastogenesis in human tunica albuginea derived fibroblasts part 1: Impact on extracellular matrix. J Sex Med 2010;7:2077-85.
22. Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie's disease. J Urol 2006;175:2115.